United States: FDA Issues Draft Guidance On Use Of Patient Preference Information In Certain Medical Device Pre-Market Submissions And Labeling

Last Updated: May 28 2015
Article by Lynn Tyler and Hae Park-Suk

The Food and Drug Administration (FDA) recently issued a draft guidance titled, "Patient Preference Information – Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling." The draft guidance may be viewed as a supplement to an earlier guidance titled, "Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications." In the earlier guidance, FDA stated that its reviewers may consider certain data measuring patient perspectives during the premarket review process for premarket approval applications (PMAs) and de novo classification requests. In other words, patient tolerance for risk and perspective on benefit may be considered in FDA's assessment of the benefit-risk profile of certain devices when the information meets FDA's standards for valid scientific evidence.

The draft guidance defines "patient preference information" as "qualitative or quantitative assessments of the relative desirability or acceptability of attributes that differ among alternative diagnostic or therapeutic strategies." The draft guidance states that it may be useful for sponsors to collect and submit patient preference information for PMAs, humanitarian device exemption (HDE) applications, and de novo requests, particularly where usage decisions by patients and health care professionals are "preference-sensitive." Preference-sensitive decisions may be required when a patient has multiple treatment options and there is no option that is clearly superior for all preferences, when the evidence supporting one option over others is considerably uncertain or variable, and/or when patients' views about the most important benefits and acceptable risks of a technology vary considerably within a population.

The draft guidance states that "preference-sensitive decisions" may be presented in the following circumstances:

  • Devices with a direct patient interface
  • Devices intended to yield significant health and appearance benefits
  • Devices intended to directly affect quality of life
  • Certain life-saving but high-risk devices
  • Devices developed to fill an unmet medical need or treat a rare disease or condition
  • Devices with novel technology

Importantly, the draft guidance identifies several recommended qualities of patient preference studies. Excerpts from the guidance discussing these qualities are:

  1. Representativeness of the Sample and Generalizability of Results: A study should measure the preferences of a representative sample of adequate size to ensure that the study results can be generalized to the population of interest.
  2. Capturing Heterogeneity of Patients' Preferences: It is important to account for variations in patient gender, age, race, socioeconomic and cultural background, condition, treatment, etc., when considering patient preference information. Patient preference information should reflect the preferences of patients from the entire spectrum of disease for which the device is intended to be used. 
  3. Established Good Research Practices by Recognized Professional Organizations: The quality of a study may be established if it follows guidelines for good research practices established by a recognized professional organization.
  4. Patient Centeredness: Patient preference studies should ensure that the patient, not the health care professional, is the central part of the study. 
  5. Effective communication of benefit, harm, uncertainty, and risk: It is important for patient preference studies to define the context of the benefit-risk tradeoffs, explain the level of effectiveness and the severity of treatment-related harms, and help patients conceptualize probabilities using appropriate numeric, verbal, and graphic representations of uncertainty.
  6. Minimal cognitive bias: Study design should minimize potential cognitive biases such as framing (e.g., describing changes as gains or losses), anchoring (e.g., signaling a reference value), simplifying heuristics (e.g., recoding numerical values or percentages as low, medium, and high), or ordering effect (e.g., the response to a question depending on its relative position in the question sequence). 
  7. Logical soundness: The data should include internal validity tests of logic and consistency and should be verified for conformity with logic and consistency.
  8. Relevance: Critical aspects of risk, benefit, and uncertainty should be included in the elicitation of preferences, and omission of any should be well justified.
  9. Robustness of Analysis of Results: After measurements are made in a scientific study, an analysis of these results should ensure appropriate interpretation of the collected evidence.
  10. Study Conduct: The validity and reliability of study results depends in large part on compliance of research staff and study participants with the study protocol. 
  11. Comprehension by Study Participants: Efforts should be made to ensure that study participants fully understand the risk and other medical information being communicated to them.

The guidance also addresses use of patient preference information in labeling. For a device for which FDA considers patient preference information in its benefit-risk determination, the guidance states that in addition to the standard elements of labeling (e.g., indications for use, contraindications, benefits, risks, warnings, and user instructions), the labeling should describe the patient preference study data, including the range of patient preferences and characteristics of patients who considered the device's probable benefits to outweigh its probable risks.

Generally, labeling should be written in plain language so that patients are able to understand the information presented and form realistic expectations of the treatment and its potential risks. The patient labeling should use terminology and numerical data in a way that is easily recognized and understood by the average layperson. When appropriate, pictorials, graphics, or tables, should be included as an adjunct to the written word. In addition, the labeling should include a clear indication of the population for whom the device is appropriate.

The patient labeling should contain information that may assist patients in understanding:

  • if they might benefit from use of the device,
  • the potential benefits from use of the device,
  • the potential risks or complications from use of the device, and the likelihoods of each,
  • any relevant contraindications, warnings, and precautions,
  • if they share characteristics with the group of patients who view the benefits as outweighing the risks, and
  • any additional information about what is known and not known about patient outcomes (e.g., long-term outcomes, rare complications).

Health care professional labeling should include a summary of the patient preference study, which describes the population studied, the method used to elicit patient preferences, attributes and levels of benefit and risk included in the design, and results of the study.

A copy of the draft guidance document can be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions